Estrogens stimulate proliferation of estrogen receptor positive MCF7 breast cancer cells while antiestrogens signal a G0/G1 growth arrest. In MCF7 cells, arrest is mediated through the CDK inhibitors p21 and p27 and through a decrease in cyclin E/CDK2 kinase activity. We found that in MCF7 cells, overexpression of cyclin E partially abrogates a tamoxifen mediated growth arrest. Overexpression of cyclin E is accompanied by a decrease in the levels of RB and CDK inhibitor p21 but an increase in CDK inhibitor p27. Cyclin E overexpression also alters the composition of E2F transcription factor complexes. The E2F4/p107/cyclin E/CDK2 complex, a minor component in proliferating control cells that is absent in growth-arrested cells, is more abundant in both proliferating and tamoxifen treated cyclin E overexpressing cells. Conversely, levels of the quiescence associated E2F/p130 complex is not detected in these cells. Expression from the E2F dependant promoter is elevated in proliferating and tamoxifen treated cyclin E overexpressing cells. This study suggests that a modest overexpression of cyclin E abrogates the tamoxifen mediated growth arrest through modification of the RB/E2F pathway. Moreover, these results provide one explanation of why some cells that express the estrogen receptor may be unresponsive to antiestrogens.
Introduction
Most estrogen receptor positive (ER+) mammary carcinomas are dependent on estrogen for growth (Perlmann and Evans, 1997) . Estrogens exert their mitogenic properties by binding to the ER and inducing conformational changes thereby regulating its phosphorylation and recruitment of other coregulatory proteins to promote ER dependent transcription (Perlmann and Evans, 1997; Beato et al., 1996; Katzenellenbogen et al., 1996) . Selective estrogen receptor modulators (SERMs) like tamoxifen and 4-hydroxytamoxifen compete with estrogen for ER binding and inhibit the growth of ER+ tumors by arresting cells in G0/G1 (Taylor et al., 1983) . Antiestrogens are initially effective in halting the growth of many ER+ tumors, but for unknown reasons some tumors that are ER+ do not respond to this treatment. In addition, hormonally responsive cancers eventually develop resistance despite the presence of an intact ER (Encarnacion et al., 1993; Robertson, 1996; Howell et al., 1996) . This suggests that additional alterations promote proliferation in the presence of antiestrogens, allowing the cells to become independent of this signaling pathway.
Proliferation in eukaryotes is regulated by the sequential activation and inactivation of specific cyclin dependent kinases (CDKs) that act to promote passage through the cell cycle (Hartwell and Kastan, 1994; Sherr, 1994 Sherr, , 1996 Nasmyth, 1993) . Activation of the CDKs is dependent on an interaction with the cyclin regulatory subunit, resulting in a cascade of protein phosphorylation that is required for cell cycle progression (Nasmyth, 1993) . Inhibition of CDK activity results in cell cycle arrest (Sherr and Roberts, 1999) while deregulation of certain cyclins correlates with deregulated growth controls and transformation (Buckley et al., 1993; Hunter and Pines, 1994) .
The mechanism by which cyclin E participates in mammary tumorigenesis is unclear. Studies have documented that cyclin E overexpression and increase in cyclin E/CDK2 kinase activity correlates with poor prognosis (Keyomarsi et al., 1994; Nielsen et al., 1996) . Also, the progression of benign breast tissue through ductal carcinoma in situ to invasive ductal carcinoma is associated with accumulating levels of cyclin E. Therefore, the severity of cyclin E alterations correlates with tumor stage and grade (Keyomarsi et al., 1994) . It has also been noted that some breast tumors not only have an overexpression of cyclin E, but also have multiple forms of the protein, including truncated forms that are constitutively active (Keyomarsi et al., 1995) . The importance of cyclin E in breast tumorigenesis is also supported by studies in transgenic mice where overexpression of cyclin E in mouse mammary breast epithelium results in the induction of hyperplasia and carcinomas (Bortner and Rosenberg, 1997) .
Cyclin E acts at the G1/S stage of cell cycle and is essential for the transversal of this checkpoint (Duronio et al., 1996; Ohtsubo et al., 1995) . Several substrates of cyclin E have been identified, including the retinoblastoma gene product (RB), BRCA1, minichromosome maintenance proteins, CDC45-associated proteins, and NPAT (Hatakeyama et al., 1994; Ruffner et al., 1999; Su and O'Farrell, 1997; Arata et al., 2000; Zhao et al., 1998) . Cyclin E/CDK2 also phosphorylates p27, a CDK inhibitor, altering its stability and promoting ubiquitin-mediated proteolysis (Vlach et al., 1997; Sheaff et al., 1997; Swanson et al., 2000) . In turn, p27 associates and inhibits the activity of cyclin E/CDK2 (Zerfass-Thome et al., 1997; Koff et al., 1993; Hengst et al., 1994) . Therefore, p27 is both an inhibitor and substrate of the cyclin E/CDK2 complex, suggesting an autoregulatory loop. Studies have found that reduction in the levels of p27 in primary breast cancers correlates with both estrogen independence and poor survival (Chiarle et al., 2001) . Estrogen depletion or treatment with antiestrogens causes a G1 growth arrest of the mammary tumor derived MCF7 cell line. Previous studies report that this arrest is accompanied by the elevation of both p21 and p27 as well as a decrease of cyclin E associated kinase activity (Watts et al., 1995; Cariou et al., 2000) . Cariou et al. (2000) reported that antisense p21 or p27 oligonucleotides are able to abrogate the antiestrogen mediated growth arrest thus arguing that both CDK inhibitors are crucial mediators of antiestrogens and that inhibition of cyclin E/CDK2 is essential for enforcement of the G1 growth arrest.
In the present study we show that a threefold overexpression of cyclin E in estrogen dependent MCF7 cells (MCF7-CycE) promotes cell cycle progression in estrogen depleted media and in the presence of tamoxifen. Proliferating MCF7-CycE cells have elevated rather than decreased levels of p27 protein, but decreased levels of p21. MCF7-CycE cells have lower levels of RB while the levels of p107 and p130 are unchanged. We observed alterations in E2F transcription factor complexes in proliferating cells and cells treated with estrogen depleted media and tamoxifen. Finally, expression from an E2F dependent promoter is elevated in cyclin E overexpressing cells. This study suggests that abrogation of a tamoxifen mediated growth arrest by overexpression of cyclin E is, in part, due to a deregulation of the RB/E2F pathway.
Results

Generation of MCF7 cells overexpressing cyclin E
MCF7-CycE cell lines were generated by transfection of the pRcCMV-cyclin E expression plasmid into MCF7 cells. Control cells (MCF7-Con) were generated by transfection with the parent vector pRcCMVneo. The expression of cyclin E in three different control cell lines as well as parental MCF7 cells were within 1.5-fold (data not shown). The control with the highest level of cyclin E was used as the control for all experiments. For generation of cyclin E overexpressing cells, individual clones were isolated and the levels of cyclin E were analysed by Western blot analysis. To quantitate the levels, the cyclin E blots were stripped and reblotted for actin to serve as loading controls. The intensity of the bands was quantitated by Image Quant v3.0. As shown in Figure 1 several lines have a threefold elevation in cyclin E levels. Out of 40 clones we did not isolate any clones that have high levels of expression. Since clones one and three were isolated from different transfection experiments and have the highest elevation of cyclin E, they were chosen for further analysis. The most abundant cyclin E species in control cells is about 46 KDa in size. In MCF7-CycE cells, the levels of this form increase but, in addition, a smaller molecular size variant is present in clone MCF7-CycE 3 cells. Smaller variant forms of cyclin E with different substrate specificities have previously been reported (Porter and Keyomarsi, 2000) . In control cells, the smaller size protein is barely visible.
MCF7-CycE cells escape a tamoxifen-mediated growth arrest
The cell cycle profile of both proliferating cells and cells arrested by a combination of estrogen starvation and treatment with 1 mM tamoxifen (ES/TAM) was analysed using laser scanning cytometry (LSC). 
E2F dependent transcription is elevated in MCF7-CycE cells
One mechanism by which cyclin E may abrogate the tamoxifen mediated growth arrest is by a deregulation of the E2F/RB pathway. Cyclin E/CDK2 phosphorylates RB, causing a dissociation of the E2F/RB complex derepressing E2F-mediated transcription. Cyclin E is also a component of an E2F4 complex that contains p107. To determine if E2F dependent transcription is altered in cyclin E overexpressing MCF7 cells, the E2F dependent promoter-CAT (chloramphenicol acetyl transferase) reporter plasmid (Mudryj et al., 1991) , which consists of two E2F sites and a TATA sequence, was transfected into MCF7-Con and MCF7-CycE 3 cells. Following transfection, cells were treated with ES/TAM or with regular growth media for 48 h. Cellular extracts were used in CAT assays to determine transcription levels. The results are presented as per cent of activity in proliferating MCF7 control cells (Figure 2b ). Proliferating MCF7-CycE 3 cells have approximately four times more CAT activity than control cells. Treatment of control cells and MCF7-CycE 3 cells with ES/TAM results in approximately 50% decrease in CAT activity. However, the activity in MCF7-CycE 3 cells treated with ES/TAM is still greater than the activity in proliferating control cells, thus suggesting that increased E2F dependent transcription may promote expression of proteins required for S phase even in the presence of growth arrest signals. Experiments using either estrogen depleted media or TAM alone gave similar results.
Levels of the CDK inhibitor p21 are decreased in MCF7-CycE cells
We measured cyclin E associated kinase activity of proliferating and ES/TAM treated MCF7-Con and MCF7-CycE cells. Cyclin E associated kinase activity in MCF7-CycE cells is elevated 2 -3-fold and remains higher than controls when treated with ES/TAM ( Figure 3a) .
To examine the mechanism(s) by which cyclin E partially abrogates the estrogen dependent growth arrest, the levels of the CDK inhibitors p21 and p27 were analysed. Treatment of control MCF7 cells with ES/TAM results in a 2 -3-fold increase in p27 but changes in p21 protein levels are not observed ( Figure  3b ). Comparison of proliferating MCF7-Con and MCF7-CycE cells indicate that cyclin E overexpression results in a threefold decrease in p21 levels and a 2 -3-fold increase in the p27 levels ( Figure 3b ). Treatment of MCF7-CycE cells with ES/TAM results in a further elevation of p27 but no change in levels of p21. Northern blot analysis of MCF7-CycE 3 cells indicated that the level of p27 and p21 mRNA is not altered in MCF7-CycE cells (Figure 3c ).
The protein levels of cyclins A and D were examined to determine if cyclin E overexpression results in the deregulation of these cyclins. In proliferating control and cyclin E overexpressing cells, cyclin A protein levels are similar and treatment with ES/TAM results in a decrease of cyclin A in control and a more pronounced decrease in MCF7-CycE cells (Figure 3b ). Similar results were obtained for cyclin D.
Analysis of RB, p107 and p130
Cyclin E/CDK2 is involved in the phosphorylation of RB, a tumor suppressor that in its hypophosphorylated form interacts with E2F1, 2 and 3 to repress transcription of growth promoting genes (Nevins, 1998; Dyson, 1998; Mayol and Grana, 1997) . Cyclins D and E sequentially phosphorylate RB to generate a hyperphosphorylated molecule that can no longer interact with E2F, thus relieving repression (Lundberg and Weinberg, 1998; Harbour et al., 1999) . Both p130 and p107 interact with E2F4. The p130/E2F4 complex is present in G0/G1 and in differentiated cells while the p107/E2F4 complex, in association with CDK2 and either cyclin E or cyclin A, is present during S phase in proliferating cells (Mudryj et al., 1991; Lees et al., 1992) . RB, p107 and p130 were analysed in proliferating MCF7-Con cells and MCF7-CycE. As shown in Figure 3d , RB levels are decreased in cyclin E overexpressing cells. Control cells treated with ES/ TAM have increased RB levels and an increase of hypophosphorylated RB. MCF7-CycE cells treated with ES/TAM have a decrease in hyperphosphorylated RB and an increase in hypophosphorylated RB. However, the overall levels of RB remain low in MCF7-CycE cells. Consistent with previous observations (Carroll et al., 2000) , MCF7-Con cells treated with ES/TAM have reduced levels of p107, increased levels of p130, and an increase in the hyperphosphorylated form of p130 (Figure 3d ). MCF7-CycE cells respond in a similar manner. The protein levels of the transcription factors E2F1 are decreased in cells treated with ES/TAM and remain the same between control and cyclin E overexpressing cells, while the levels of E2F4 remain the same. This analysis suggests that a decrease in RB levels is associated with entry into S phase under growth arrest conditions.
Persistence of the E2F/p107/cyclin E/CDK2 complexes in ES/TAM treated MCF7-CycE cells
Since alterations were noted in levels of RB, we characterized the interactions of RB, p107 and p130 with E2F by electrophoretic mobility gel shift analysis (EMSA). In previous studies, treatment of MCF7 cells with the antiestrogen ICI 182780 induces quiescence and accumulation of the p130 protein and E2F4/p130 complex (Carrol et al., 2000) . All gel shift analyses were conducted with extracts prepared from MCF7-Con and MCF7-CycE 3 cells, the clone with the highest level of cyclin E. The gel shift analyses show that proliferating MCF7-Con and MCF7-CycE cells have an E2F/RB complex, a more slowly migrating E2F4/p107/cyclin complex, and 'free' E2F ( Figure 4a,c  and d) . The RB and p107 complexes were identified by supershift analysis with specific antibodies (Figure  4c,d) . Addition of cyclin A or cyclin E specific antibodies indicates that in proliferating MCF7-Con cells, the p107 complex contains mostly cyclin A (Figure 4e) , while the p107 complex in MCF7-CycE cells contains mostly cyclin E (Figure 4f ). All gel shift analyses were performed alongside appropriate controls. One representative control is shown ( Figure  4a ).
MCF7-Con cells treated with ES/TAM have a new complex that is not affected by the addition of p107 specific antibodies (Figure 4a,d) . In previous studies this complex has been shown to contain p130 (Mayol and Grana, 1997) . The p130 antibody supershifts this complex and the p107 containing complex. In MCF7-CycE cells treated with ES/TAM, the p130 complex is absent while the E2F/p107/cyclin E complex persists. In summary, the gel shift studies indicate that MCF7-CycE cells contain predominantly a cyclin E/p107 complex while in control cells, the predominant complex contains cyclin A. Furthermore, cyclin E containing p107 complexes persist in ES/TAM treated MCF7-CycE 3 cells, while in control cells a faster migrating p130 complex replaces the p107/cyclin complex.
To further analyse the association of cyclin E with E2F/p107 complexes, extracts were subjected to immunoprecipitation with cyclin E, RB or p107 antibodies followed by EMSA. As shown in Figure  5a , the amount of E2F/cyclin E complex in proliferating MCF7-Con cells is low and is undetectable in cells treated with ES/TAM. However, the amount of E2F in a complex with cyclin E is greatly increased in both proliferating and ES/TAM treated MCF7-CycE cells. Addition of anti-E2F1 or anti-E2F4 antibodies indicates that cyclin E is present in a complex with E2F4, Figure 5b , the level of E2F in RB immunoprecipitates is slightly decreased in proliferating MCF7-CycE cells. Also, immunoprecipitation with p107 antibodies followed by EMSA reveal that E2F is associated with p107 in MCF7-Con, MCF7-CycE cells, and MCF7-CycE cells treated with ES/TAM but not in MCF7-Con cells treated with ES/ TAM. We conclude that overexpression of cyclin E alters the composition of the E2F complexes and in cells treated with ES/TAM, cyclin E overexpression promotes the persistence of the E2F/p107/cyclin E complex but inhibits the formation of the E2F/p130 complex.
Discussion
Numerous studies establish that cyclin E is overexpressed in 20 to 25% of breast tumors. Also, reports indicate that some ER+ cells are unresponsive to antiestrogens such as tamoxifen. More recent studies suggest that the expression of p21 and p27 and the inhibition of cyclin E dependent kinase activity mediate the antiestrogen growth arrest in MCF7 cells. Therefore, we reasoned that overexpression of cyclin E in estrogen dependent cells might override the response to tamoxifen. Our data indicates that a modest threefold increase in cyclin E levels is sufficient to partially (Schulze et al., 1995) . The decrease of cyclin A and D in cells treated with ES/TAM suggest that an increase of these cyclins is not required for entry into S phase.
Since CDK inhibitors have a role in tamoxifen mediated growth arrest they are likely targets of cyclin E/CDK2. Previous in vitro studies suggest that when levels of cyclin E are sufficiently high, p27 becomes degraded, arguing that the ratio of p27 and cyclin E is an important determinant for p27 (Swanson et al., 2000) . We found that a threefold elevation of cyclin E is coincident with slightly increased p27 levels. This result is consistent with a previous study where transfection of cyclin E into the HC11 mouse mammary epithelial cell line results in an increase of p27 (Sgambato et al., 1996) . It is possible that the levels of cyclin E in our clones are not sufficiently high to trigger p27 degradation. It is also possible that the effect of cyclin E on p27 levels is determined not only by cyclin E levels but also by the cellular context. Northern blot analysis indicates that the increase in p27 is governed by post-transcriptional events. Several mechanisms may account for this increase. When cyclin E levels are increased there may be a redistribution of p27 between complexes that serves to protect p27 from degradation. Alternatively, cyclin E may indirectly enhance the rate of p27 translation. Cyclin E overexpression has the opposite effect on p21 protein levels. The decrease in p21 is due to post-transcriptional controls. This may be due to protealytic degradation mediated by ubiquitin dependent (Maki and Howley, 1997) or independent mechanisms (Sheaff et al., 2000) . We did not observe an increase in p21 levels when cells are treated with antiestrogens as reported previously (Cariou et al., 2000) . In our study we used tamoxifen rather than ICI 182780, and the two antiestrogens may have slightly different affects.
Elevation in cyclin E results in reduced levels of RB, which is present in its hyperphosphorylated form. Treatment of cyclin E overexpressing cells with ES/ TAM does not alter the RB protein levels, but the protein does become hypophosphorylated. The level of the RB related protein p107 is unchanged. Previous studies report that antiestrogen mediated growth arrest is associated with both a decrease in p107 and an increase in p130 and p130 phosphorylation (Cariou et al., 2000) . We observed identical changes when control and cyclin E overexpressing cells were treated with ES/ TAM. However, a substantial percentage of the cyclin E overexpressing cells enter S phase, suggesting that changes in p107 and p130 levels are not sufficient to prevent entry into S phase.
The composition of the E2F complexes is altered in proliferating MCF7-CycE cells. A threefold increase in cyclin E levels is sufficient for cyclin A to be replaced with cyclin E, suggesting that the ratio of cyclin A to cyclin E may determine complex composition. Consistent with previous studies, when MCF7-Con cells are growth arrested by antiestrogens, the E2F/p130 complex replaces the cyclin containing complexes. However, in MCF7-CycE cells treated in the same manner, the E2F4/p107/cyclin E complex persists and the E2F/p130 complex is absent. Since the levels and phosphorylation of p130 are not altered by cyclin E overexpression, the presence of this complex is not dependent solely on the protein levels and/or phosphorylation state of p130. p107 protein levels are also not altered in cyclin E overexpressing cells, but the p107/cyclin E complex persists in growth arrest conditions. This suggests that the formation of p130 or p107 complexes is dependent on the presence of cyclins. Only a slight alteration in the levels of E2F/RB complexes is detected in the immunoprecipitation/ EMSA assays. Our assay system may not be sensitive enough to detect the minor change in E2F/RB complex levels. In addition, the decrease in RB levels may affect other signaling pathways to promote S phase entry.
In conclusion this study suggests a link between modest overexpression of cyclin E and diminished response to tamoxifen. Using the MCF7 breast tumor cell line we analysed the molecular event initiated by an increase in cyclin E. These include an alteration in expression of the CDK inhibitors p21 and 27, as well as alterations in cyclins A and D. The decrease in RB levels and the alteration of E2F complex composition is coincident with a deregulation of E2F-dependent transcription and continued entry into S phase in the presence of tamoxifen. We propose that in this system even a modest increase of cyclin E, through a modulation of E2F pathway, circumvents the requirement for estrogen and overrides an antiestrogen mediated growth arrest.
Materials and methods
Cell lines
The MCF7 cell line was obtained from American Type Culture Collection (Manassas VA, USA) and propagated in RPMI (Gibco/BRL, Rockville, MD, USA) supplemented with 5% FBS, Penicillin/Streptomycin (P/S) at 378 and 5% CO 2 . Cyclin E overexpressing lines were generated by transfection with the pRcCMV-cyclin E plasmid (gift from Dr P Hines). The control vector pRcCMVneo was obtained from Invitrogen (Carlsbad, CA, USA). After transfection the cells were placed in media containing 400 mg/ml of geneticin (Gibco/BRL), and individual colonies were isolated and propagated in media containing 400 mg/ml geneticin. For studies in estrogen depleted media, the cells were grown for 48 h in RPMI supplemented with 5% charcoal treated serum (Gibco/BRL) and P/S. Tamoxifen was obtained from Sigma (St. Louis, MO, USA).
Laser scanning cytometry
Cells were plated on two chamber slides at a density of 5610 5 cell/cm 2 . To determine the percentage of cells in S phase the cells were labeled with 25 mM BrdU (Bromodeoxyuridine-Sigma) for 2 h, washed in PBS (phosphate buffered saline) pH 7.4, fixed in Histochoice (Amresco, Solon, OH, USA) for 10 min, and washed again in PBS containing 0.5% Tween for 5 min. The cells were then dehydrated in 70, 90 and 100% ethanol. Slides were placed in PBS for 1 min, 0.07N NaOH for 2 min, and PBS for 2 min. 100 ml of a solution containing 28.5 ml Anti-Brdu-FITC (Becton Dickinson, Franklin Lakes, NJ, USA), 250 mg/ml RNase, and 1.0 mg/ml propidium iodide was applied to each slide. Slides were incubated for 30 min at 378C. Cells were then washed three times with PBS (0.5% Tween) for 5 min each. 20 ml of Mounting Solution (1.0 mg/ml PI, 2M 1-1-Diazabicyclo[2.2.2.]octane or DABCO, 50% Glycerol) was applied to each region of the slide. Incorporation of BrdU was measured using a laser scanning cytometer (CompuCyte Corp, Cambridge, MA, USA) (Kamentsky, 2001) , and fluorescence was measured as described (Darzynkiewicz et al., 1999) .
Immunoblot analysis
Cells were lysed in RIPA buffer and equal amounts of protein were separated on 8, 10, or 12% SDS -PAGE gels. Each gel was transferred to BA-85 membrane (Schleicher and Schuell, Keene, NH, USA). The membrane was blocked with 5% nonfat dry milk in phosphate buffered saline (PBS) and 0.1% Tween for 1 h before the addition of specific antibodies. The following antibodies were used: cyclin E antibody was a generous gift from Dr G Lozano, anti-p21, anti-p27, anti-cyclin A, anti-cyclin D, p107, p130, CDK2, actin, E2F1, and E2F4 from Santa Cruz (Santa Cruz, CA, USA, RB from Pharmingen (Franklin Lakes, NJ, USA). After incubation with secondary mouse monoclonal or rabbit polyclonal horseradish-peroxidase linked NIF 825 antibodies (Amersham Pharmacia, Piscataway, NJ, USA) proteins were detected using ECL (Amersham Pharmacia) following manufacturer's recommendations. Image Quant V.3.0 (Molecular Dynamics, Sunnyvale, CA, USA) software was used to quantitate protein levels.
In vitro kinase assays
In vitro kinase assays were performed as previously described (Mudryj et al., 1991) . Briefly, cells were lysed in NP40 lysis buffer, the extracts were pre-cleared and incubated with specific antibodies. The antibody/protein complexes were isolated on protein A/Protein G agarose beads (Oncogene Science, Cambridge, MA, USA), washed, and resuspended in kinase buffer (1 mg/ml Histone H1, 1 mM ATP, 1 mCi/mlg 32 P ATP, 20 mM HEPES pH 7.0, 80 mM b-glycerolphosphate, 20 mM EGTA, 50 mM MgCl 2 , 5 mM MnCl 2 , 1 mM DTT, 2.5 mM PMSF, 10 mM camp protein kinase inhibitor). The kinase reaction was terminated by addition of gel loading buffer and the protein was separated on 12% SDS -PAGE. The gel was fixed, dried, and autoradiographed.
Electrophoretic mobility shift assay and IP/EMSA
Whole cell extracts were prepared as described previously (Mudryj et al., 1991) . The assay for E2F binding activity contained 0.5 ng of 32 P-labeled E2 promoter fragment, 20 ml of gel shift buffer (20 mM HEPES (pH 7.4), 1 mM MgCl 2 , 0.1 mM EGTA, 0.5 mM DTT, 40 mM KCl, 2 mg sonicated salmon sperm DNA, 60 mg BSA, 1% ficoll, 1% NP40), and 5 mg cell extract and performed as previously described (Mudryj et al., 1991) . The probe was an EcoRI-HindIII fragment from the ATF(7) adenovirus E2 promoter plasmid (Loeken and Brady, 1989) . Coupled immunoprecipitations-EMSA assays were performed as follows. Whole cell extracts (50 mg) were precleared with protein G/protein A agarose beads (Oncogene Science) for 20 min at 48C. Supernatant was removed and incubated with the cyclin E, RB, or p107 antibodies for 1 h at 48C in buffer containing 20 mM HEPES (pH 7.4), 50 mM KCl, 0.4 mM NaF, 0.1 mM NaVO 4 , 0.5 mM Pefablock, 1 mM DTT, 10% glycerol, and 0.1 mM EDTA. Protein G Plus/protein A agarose beads were added and the mixture was incubated for 1 h at 48C. The beads were centrifuged and washed four times with 500 ml of gel shift buffer containing 3 mg/ml BSA. Beads were then incubated in the presence of 6 ml gel shift buffer containing 0.8% deoxycholate for 10 min at room temperature. The beads were centrifuged and the supernatant was treated with NP-40 and used in an E2F binding assay.
Northern blot analysis
Total RNA was isolated using the Trizol reagent (Gibco/ BRL) following manufacturer's recommendation. 10 mg of total RNA was electrophoresed on a 1% agarose gel and transferred to Duralon-UV membrane (Stratagene, La Jolla, CA, USA) according to manufacturer's protocol. The following primers were used to generate p21 and p27 specific RT -PCR products: p21 5'-GACACCACTGGAGGGTGA-CT-3' and 5'-GGCGTTTGGAGTGGTAGAAA-3', p27 5'-AGTTAACCCGGGACTTGGAG-3' and 5'-TGTCCGACG-GATCAGTCTTT-3'. p21 and p27 specific RT -PCR products were labeled with a 32 P-dCTP to generate probes. The hybridization and wash conditions were previously described (Sambrook et al., 1989) . The radioactive filters were exposed to Kodak X-OMAT film.
Transfection
Cells were transfected with Superfect reagent (Qiagen, Valencis, CA, USA) and 5 mg of pE2-CAT plasmid following manufacturer's recommendation. Forty-eight hours after transfection, cells were harvested and subjected to analysis as previously described (Mudryj et al., 1991) .
